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852 Strober et alResults: Of 2541 new users on registry, 2076 had efficacy data: ustekinumab (n = 1041), infliximab (n = 116),
adalimumab (n = 662), and etanercept (n = 257). Patients receiving tumor necrosis factor-alpha(-a)
inhibitors were significantly less likely to achieve Physician Global Assessment score 0/1 versus
ustekinumab (infliximab [odds ratio {OR} 0.396, P\ .0001], adalimumab [OR 0.686, P = .0012], etanercept
[OR 0.554, P = .0003] at 6 months and infliximab [OR 0.449, P = .0040] at 12 months). Mean decrease
in percentage of body surface area with psoriasis was significantly greater for ustekinumab versus
adalimumab (point estimate 1.833, P = .0020) and etanercept (point estimate 3.419, P\ .0001) at 6 months
and versus infliximab (point estimate 3.945, P = .0005) and etanercept (point estimate 2.778, P = .0007) at
12 months.Limitations: Treatment selection bias and limited data for doing adjustments are limitations.Conclusions: In PSOLAR, effectiveness of ustekinumab was significantly better versus all 3 tumor
necrosis factor-a inhibitors studied for the majority of comparisons at 6 and 12 months. ( J Am Acad
Dermatol 2016;74:851-61.)
Key words: adalimumab; biologic; BSA; DLQI; effectiveness; efficacy; etanercept; infliximab; PGA;
PSOLAR; Psoriasis Longitudinal Assessment and Registry; ustekinumab.Comparative effectiveness data are important to
both the physician and patient for differentiatingCAPSULE SUMMARY
d Several biologics are effective for the
treatment of psoriasis.
d In a real-world setting, effectiveness was
significantly better for ustekinumab than
for tumor necrosis factor-a inhibitors for
the majority of comparisons at 6 and
12 months.
d These comparative effectiveness
analyses of currently available biologic
therapies will help inform treatment
decisions in patients with psoriasis.between treatment options
when selecting a therapy,
especially as the options for
biologic therapy continue
to expand.1 Consequently,
there is increasing demand
for comparative effective-
ness data in the current
health care environment to
better inform patients and
physicians when choosing
appropriate treatments for
psoriasis.2-4 Selection of ther-
apy depends on numerous
factors, including efficacy,
safety, response over time,
convenience, and afford-
ability. Furthermore, some studies have demon-
strated a correlation between measures of health-
related quality of life (HRQoL) and effectiveness,
indicating the importance of patient-reported out-
comes.5-10 To date, a number of head-to-head
clinical trials and meta-analyses have been
performed to compare the efficacy of various
biologic agents for psoriasis; results pertain largely
to short-term outcomes and do not always reflect
findings in typical practice.11-19 In addition,
real-world evidence of comparative effectiveness of
biologics is generally lacking, with few such studies
reported in the literature.20-22
Psoriasis Longitudinal Assessment and Registry
(PSOLAR) is an ongoing, longitudinal, prospective,
international, observational study that follows pa-
tients with psoriasis who are receiving, or are eligibleto receive, systemic or biologic therapies.23,24 In
addition to generating safety data on biologic ther-apies, this registry also cap-
tures data relevant to the
effectiveness of biologics for
patients with psoriasis. The
objective of this analysis is to
compare the effectiveness
of tumor necrosis factor
(TNF)-a inhibitors (inflixi-
mab, adalimumab, and eta-
nercept) with effectiveness
of ustekinumab based on
standard clinical and HRQoL
measures (ie, Physician
Global Assessment [PGA],
percentage of body surface
area with psoriasis [%BSA],
and Dermatology LifeQuality Index [DLQI]) after 6 and 12 months of
treatment.METHODS
The design and utility of PSOLAR have been
reported previously.23,24 A core set of data
(including disease activity, HRQoL, medications,
and adverse events) are collected every 6 months.
Physicians prescribe treatments based on routine
clinical practice. PSOLAR enrollment is complete;
data for these analyses cover the period from June
20, 2007, to August 23, 2013. In all, 93 institutional
review boards or ethics committees approved the
registry protocol, and all patients provided written
informed consent before study procedures were
initiated.
Table I. Factors other than treatment effects
included in multivariate analyses of effectiveness in
Psoriasis Longitudinal Assessment and Registry
d Age at diagnosis/10 y*
d Duration of disease/5 y*
d Region: European Union/Latin America vs North America
d Race: non-white vs white
d Gender: male vs female
d Overweight/obesity class I (25\ BMI\ 35) vs normal
weight (BMI\25)
d Obesity class II-III (BMI $35) vs normal weight (BMI\25)
d Psoriatic arthritis vs no psoriatic arthritis at baseline
d Smoking (current/past vs never) at baseline
d Alcohol (current/past vs never) at baseline
d PGA score 2/3 vs 0/1 at baseline
d PGA score 4/5 vs 0/1 at baseline
d Percentage of BSA with psoriasis at baseline
d DLQI score $10 vs\10 at baseline
d Discontinued because of adverse event vs continued in
registry
d Discontinued insurance vs continued in registry
d Discontinued (other reason)y vs continued in registry
d Prior treatment with tumor necrosis factor-a inhibitors
vs bionaive
d Prior treatment with ustekinumab vs bionaive
d Prior treatment with other biologicsz vs bionaive
BMI, Body mass index; BSA, body surface area; DLQI, Dermatology
Life Quality Index; PGA, Physician Global Assessment.
*To evaluate odds ratio for every 10-y increase in age or every 5 y
of disease, baseline continuous variables of age and duration of
disease were transformed to age divided by 10 and duration of
disease divided by 5.
yDiscontinued (other reason) included all reasons except adverse
event and insurance.
zPrior other biologics included any biologic other than
ustekinumab or a tumor necrosis factor-a inhibitor.
Abbreviations used:
%BSA: percentage of body surface area with
psoriasis
CI: confidence interval
DLQI: Dermatology Life Quality Index
HRQoL: health-related quality of life
OR: odds ratio
PGA: Physician Global Assessment
PSOLAR: Psoriasis Longitudinal Assessment and
Registry
SD: standard deviation
TNF: tumor necrosis factor
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The study population included 4 treatment groups
of patients initiating a new biologic (ustekinumab,
infliximab, adalimumab, or etanercept); only the first
biologic started during registry participation was
analyzed. Patients may have been bionaive or may
have been exposed before enrollment to a biologic
other than their newly initiated treatment in the
registry. Patients restarting a biologic received before
enrollment were excluded from the analyses.
Evaluations were limited to patients who had baseline
data and continued to receive their initiated therapy at
their 6- and/or 12-month visits. Baseline psoriasis
severity was assessed at the closest visit before the
first dose of the newly initiated biologic. Patients
receiving concomitant treatment with another
systemic therapy for psoriasis (eg, methotrexate,
cyclosporine, mycophenolate mofetil, fumarates,
oral retinoids, apremilast, or systemic corticosteroids)
or phototherapy were excluded, although patients
receiving topical therapy (eg, retinoids and corticoste-
roids) were included in the analyses.
Outcome measures
Clinical effectiveness was measured based on PGA
(ie, induration, scaling, and erythemaof lesions graded
on a scale ranging from clear [0] to severe [5]) and
%BSA.HRQoLwas assessedusing theDLQI,which is a
skin disease-specific, patient-reported questionnaire
assessing 10 items, with an overall potential score
ranging from 0 (not affected at all) to 30 (very much
affected).25 A DLQI score of 0 or 1 indicates no impact
on a patient’s life, and a decrease of 5 or more points is
considered clinically meaningful.26
Statistical analyses
Baseline information captured at the time of
starting a new biologic is presented for each of the
biologics. Clinical effectiveness end points included
the proportion of patients achieving a PGA score of
0/1, the proportion of patients achieving a reduction
of 2 or more points in PGA score, and the meandecrease in %BSA across treatment groups at 6 and
12 months. HRQoL end points included mean
improvement in DLQI score and the proportion of
patients achieving a clinically meaningful change (ie,
reduction $5 points) in DLQI score stratified by
baseline score (ie,\10 and $10) among treatment
groups at 6 and 12 months.
Data were captured for each study visit within a
maximum window of 63 months; if the visit
occurred outside of this window, data were not
included in the analyses. If 2 visits fell within a given
follow-up time window, data from the visit closest to
the designated time point were used. Patients who
discontinued because of lack of effectiveness before
a scheduled time-point visit were considered
treatment failures (ie, PGA score was entered as
not achieving clear [0] or minimal [1], and the change
from baseline was entered as 0 for %BSA and DLQI
score) for that and all subsequent scheduled visits.
Table II. Demographic and patient characteristics at enrollment or start of a new biologic (baseline) during the
registry
Ustekinumab
N = 1041
Infliximab
N = 116
Adalimumab
N = 662
Etanercept
N = 257
Total
N = 2076*
Age, y, N 1041 116 662 257 2076
Mean 6 SD 46.3 6 13.54 47.9 6 13.15 46.7 6 13.59 46.8 6 13.94 46.5 6 13.58
Age at onset of psoriasis,y y, N 1035 116 658 255 2064
Mean 6 SD 27.7 6 15.31 31.2 6 14.25 31.1 6 15.57 32.6 6 16.41 29.6 6 15.59
Male gender,y N 1041 116 662 257 2076
n (%) 591 (56.8) 73 (62.9) 384 (58.0) 144 (56.0) 1192 (57.4)
White race,y N 1041 116 662 256 2075
n (%) 900 (86.5) 106 (91.4) 511 (77.2) 216 (84.4) 1733 (83.5)
BMI, kg/m2, N 1032 116 658 252 2058
Mean 6 SD 31.2 6 7.15 32.6 6 7.57 30.5 6 6.70 30.0 6 7.04 30.9 6 7.04
Years since psoriasis diagnosis, y, N 1035 116 658 255 2064
Mean 6 SD 19.1 6 13.07 17.2 6 12.35 16.1 6 12.17 14.7 6 13.19 17.5 6 12.86
Psoriatic arthritis,y N 1041 116 662 257 2076
n (%) 349 (33.5) 51 (44.0) 232 (35.0) 92 (35.8) 724 (34.9)
Prior therapy
Biologic agents, N 1041 116 662 257 2076
Ustekinumab 0 16 (13.8) 43 (6.5) 10 (3.9) 69 (3.3)
Infliximab 179 (17.2) 0 47 (7.1) 18 (7.0) 244 (11.8)
Adalimumab 389 (37.4) 42 (36.2) 0 39 (15.2) 470 (22.6)
Etanercept 497 (47.7) 48 (41.4) 339 (51.2) 0 884 (42.6)
Other therapies, N 1040 115 662 257 2074
Phototherapy 648 (62.3) 60 (52.2) 344 (52.0) 106 (41.2) 1158 (55.8)
Immunomodulators 538 (51.7) 64 (55.7) 258 (39.0) 100 (38.9) 960 (46.3)
Methotrexate 430 (41.3) 49 (42.6) 214 (32.3) 81 (31.5) 774 (37.3)
Cyclosporine 247 (23.8) 25 (21.7) 93 (14.0) 28 (10.9) 393 (18.9)
Data are presented as no. of patients (%), unless otherwise indicated.
BMI, Body mass index; SD, standard deviation.
*Total includes patients who continued to receive their initiated therapy at the 6- and/or 12-mo visit and for whom data were available for at
least 1 visit. Patients who discontinued because of lack of effectiveness were included as treatment failures (ie, not achieving PGA score of
0/1 and no changes from baseline for %BSA and DLQI) at subsequent visits.
yData were collected at enrollment in the Psoriasis Longitudinal Assessment and Registry; all other data were collected at the start of
therapy.
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to follow-up were not included in the analyses.
The proportions of patients achieving PGA score
of 0/1 at 6 and 12 months were evaluated using a
logistic regression model. Adjusted odds ratios (OR),
95% confidence intervals (CI), and corresponding
P values (Wald x2 test) were calculated for
the treatment effect of each TNF-a inhibitor (inflix-
imab, adalimumab, and etanercept) compared with
ustekinumab at 6 and 12 months. Covariates other
than treatment effect were also included in the
analyses (Table I). Using the same covariates, an
analysis of covariance was performed to compare
the decrease in %BSA and improvement in DLQI
score from baseline at 6 and 12 months for each
TNF-a inhibitor versus ustekinumab. The changes in
%BSA and DLQI score for each treatment were also
summarized using the adjusted least squares means
from the analysis of covariance analysis for treatment
effects.RESULTS
Patient characteristics
Of the 2541 patients who initiated a new biologic
on registry, 2076 (ustekinumab [n = 1041], infliximab
[n = 116], adalimumab [n = 662], and etanercept
[n = 257]) had adequate data at baseline and at 6
and/or 12 months and were included in the analyses
(Table II). The mean age was 46.5 years; slightly over
half of the patients were male (57.4%) andmost were
white (83.5%). The mean duration of psoriasis was
17.5 years, ranging from 14.7 (etanercept group) to
19.1 (ustekinumab group) years. Approximately one
third of patients (34.9%) had psoriatic arthritis at
baseline; the infliximab group (44.0%) had the
highest proportion of patients with psoriatic arthritis.
Of patients included in the analyses, 42.6% had
been exposed to etanercept, 22.6% to adalimumab,
11.8% to infliximab, and 3.3% to ustekinumab before
enrollment. Before entering the registry, 55.8% of
patients had used phototherapy (numerically higher
Table III. Disease characteristics and patientereported assessments at start of new biologic treatment (baseline) and at 6 and 12 months
6 mo*y 12 moyz
Ustekinumab Infliximab Adalimumab Etanercept Ustekinumab Infliximab Adalimumab Etanercept
PGA, N 944 110 595 231 763 69 421 165
PGA 0/1 at baseline, n (%) 102 (10.8) 6 (5.5) 98 (16.5) 43 (18.6) 74 (9.7) 4 (5.8) 77 (18.3) 32 (19.4)
PGA 0/1 on registry, n (%) 539 (57.1) 40 (36.4) 298 (50.1) 117 (50.6) 452 (59.2) 29 (42.0) 238 (56.5) 95 (57.6)
PGA, Nx 835 104 492 185 683 65 344 132
$2-Point reduction, n (%) 436 (52.2) 37 (35.6) 199 (40.4) 74 (40.0) 378 (55.3) 26 (40.0) 146 (42.4) 62 (47.0)
%BSA, N 913 104 570 207 750 67 406 155
Mean 6 SD at baseline 19.9 6 19.92 25.8 6 22.99 17.0 6 20.41 18.6 6 20.26 20.4 6 19.97 26.4 6 24.92 16.8 6 19.70 19.7 6 20.81
Mean decrease 6 SD 14.7 6 19.65 17.4 6 21.50 10.6 6 18.74 11.4 6 18.29 16.3 6 18.53 17.6 6 21.23 12.3 6 19.14 13.8 6 18.77
DLQI, N 823 90 510 188 659 53 352 146
Mean 6 SD at baseline 10.3 6 7.00 12.1 6 8.08 8.6 6 6.77 10.4 6 7.33 10.2 6 6.97 11.7 6 7.68 8.2 6 6.45 9.8 6 7.44
Improvement in DLQI, N 823 90 512 188 659 53 352 146
Mean improvement 6 SD 6.9 6 7.33 6.5 6 8.10 4.5 6 6.65 6.2 6 7.21 7.5 6 7.21 6.9 6 9.11 4.9 6 6.73 5.4 6 7.72
DLQI, N 823 90 510 188 659 53 352 146
DLQI 0/1 at baseline, n (%) 50 (6.1) 7 (7.8) 54 (10.6) 13 (6.9) 38 (5.8) 1 (1.9) 41 (11.6) 11 (7.5)
DLQI 0/1 on registry, n (%) 392 (47.6) 32 (35.6) 222 (43.5) 64 (34.0) 361 (54.8) 23 (43.4) 176 (50.0) 64 (43.8)
Data are presented as n (%) unless otherwise noted.
%BSA, Percentage of body surface area with psoriasis, DLQI, Dermatology Life Quality Index, PGA, Physician Global Assessment; SD, standard deviation.
*Analyses were limited to patients who continued to receive their initiated therapy at the 6-mo evaluation visit and for whom data were available at baseline.
yPatients discontinuing because of lack of effectiveness were included in the analysis but were considered treatment failures (ie, not achieving PGA score of 0/1 and no changes from baseline
for %BSA and DLQI) at subsequent visits.
zAnalyses were limited to patients who continued to receive their initiated therapy at the 12-mo evaluation visit and for whom data were available at baseline.
xPatients with a baseline PGA score less than 2 could not be included in the analysis of PGA reduction by 2 or more points.
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Fig 1. Psoriasis. Proportion of patients with Physician
Global Assessment (PGA) score of 0 (clear) or 1 (minimal)
at 6 and 12 months; patients initiating ustekinumab,
infliximab, adalimumab, or etanercept on registry.
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used nonbiologic immunomodulators (mostly
methotrexate [37.3%]). Baseline PGA, %BSA, and
DLQI values for patients considered in the 6-month
analyses were comparable with those for patients in
the 12-month analyses (Table III). Generally,
baseline clinical values numerically reflected more
severe disease in the infliximab group. During
participation in the registry, patients generally
received treatment according to the prescribing in-
formation for the biologic agent they initiated, and
the proportion of patients receiving standard doses
at regular intervals was similar at 6 and 12 months
(Supplemental Table I; available at http://www.jaad.
org). Effectiveness data were missing for 465 patients
who could not be included in any analyses. The
infliximab group had the highest proportion of
patients with missing data (30%), whereas other
groups were missing data for 14% to 21% of patients.
In general, characteristics of the patients with
missing data were comparable with those of patients
evaluated in the analyses.
Physician Global Assessment
At 6 and 12 months, respectively, the proportions
of patients achieving a PGA score of 0/1 were 57.1%
and 59.2% for ustekinumab, 50.1% and 56.5% for
adalimumab, and 50.6% and 57.6% for etanercept;
rates for infliximab were 36.4% and 42.0% (Fig 1 and
Table III). The PGA score was reduced from baseline
by 2 or more points for 52.2% of ustekinumab, 35.6%
of infliximab, 40.4% of adalimumab, and 40.0% of
etanercept group patients at 6 months, and 55.3%,
40.0%, 42.4%, and 47.0% of patients in these groups,
respectively, at 12 months.
Adjusted logistic regression analyses showed that
patients using TNF-a inhibitors were less likely toachieve a PGA score of 0/1 at 6 months compared
with ustekinumab (infliximab vs ustekinumab [OR
0.396, 95% CI 0.255-0.617, P\.0001], adalimumab vs
ustekinumab [OR 0.686, 95% CI 0.547-0.861,
P = .0012], and etanercept vs ustekinumab [OR
0.554, 95% CI 0.400-0.765, P = .0003]) (Table IV).
Similar OR estimates were observed at 12 months,
although only the infliximab vs ustekinumab com-
parison was statistically significant (Table IV).
Factors other than treatment effect (ie, duration of
disease, region, weight, and baseline PGA score)
were significantly associated with achieving a PGA
score of 0/1 (Supplemental Table II; available at
http://www.jaad.org).
Body surface area
At 6 and 12 months, respectively, the mean
decrease in %BSA from baseline was 14.7 and
16.3 for ustekinumab, 17.4 and 17.6 for
infliximab, 11.4 and 13.8 for etanercept, and
10.6 and 12.3 for adalimumab (Fig 2 and
Table III). Analysis of covariance showed that from
baseline to 6 months patients in the ustekinumab
group demonstrated significantly better improve-
ment (ie, decreases) in %BSA compared with
adalimumab (point estimate 1.832%, 95% CI 0.670-
2.995, P = .0020) and etanercept (point estimate
3.419%, 95% CI 1.728-5.110, P \ .0001), but not
infliximab (point estimate 1.807%, 95% CI 0.368 to
3.982, P = .1033) (Table V). At 12 months, the
improvement in %BSA for infliximab and etanercept
was significantly less (point estimate 3.945%, 95% CI
1.717-6.172, P = .0005 and point estimate 2.778%,
95% CI 1.180-4.376, P = .0007, respectively)
compared with ustekinumab (but not for
adalimumab [point estimate 1.038%, 95% CI 0.068
to 2.144, P = .0659] vs ustekinumab) (Table V).
Other factors (ie, ethnicity, weight, alcohol use,
baseline %BSA, and previous TNF-a inhibitor use)
also significantly affected %BSA response
(Supplemental Table III; available at http://www.
jaad.org).
Dermatology Life Quality Index
At 6 and 12 months, respectively, the mean
improvement in DLQI score from baseline was 6.9
and 7.5 for ustekinumab, 6.5 and 6.9 for infliximab,
6.2 and 5.4 for etanercept, and 4.5 and 4.9 for
adalimumab (Table III). Among patients with a
DLQI score of less than 10 at baseline, the proportion
achieving a clinically meaningful reduction ($5) at
6 months was 54.7% (111 of 203) for ustekinumab,
53.8% (14 of 26) for infliximab, 43.9% (65 of 148)
for adalimumab, and 41.5% (22 of 53) for etanercept
(Fig 3, A). At 12 months, responses in each group
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Fig 2. Psoriasis. Mean decrease in percentage of body
surface area (%BSA) with psoriasis at 6 and 12 months;
patients initiating ustekinumab, infliximab, adalimumab,
or etanercept on registry.
Table IV. Adjusted multivariate analyses of treatment effects: logistic regression for proportion of patients
achieving a Physician Global Assessment score of clear (0) or minimal (1) at 6 and 12 months
6-mo Analysis 12-mo Analysis
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Infliximab vs ustekinumab 0.396 (0.255-0.617) \.0001 0.449 (0.260-0.774) .0040
Adalimumab vs ustekinumab 0.686 (0.547-0.861) .0012 0.841 (0.645-1.097) .2025
Etanercept vs ustekinumab 0.554 (0.400-0.765) .0003 0.686 (0.466-1.009) .0557
CI, Confidence interval.
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(ustekinumab, 58.7% [88 of 150]; adalimumab, 49.1%
[55 of 112], and etanercept, 45.0% [18 of 40]), except
for infliximab (37.5% [6 of 16]) (Fig 3, B). Among
patients with higher DLQI scores ($10) at baseline,
the proportions achieving a reduction of at least 5
points at 6 months were 86.7% [351 of 405] for
ustekinumab, 76.1% [35 of 46] for infliximab, 76.9%
[143 of 186] for adalimumab, and 82.8% [72 of 87] for
etanercept (Fig 3, A). Responses at 12 months were
91.8% (302 of 329) for ustekinumab, 74.1% (20 of 27)
for infliximab, 88.9% (104 of 117) for adalimumab,
and 72.1% (44 of 61) for etanercept (Fig 3, B). At
6 months, the proportion of patients achieving a
DLQI score of 0/1 (no impact on HRQoL) was 47.6%
in the ustekinumab group, 35.6% in the infliximab
group, 43.5% in the adalimumab group, and 34.0% in
the etanercept group; at 12 months, the proportions
were slightly higher across all treatment groups
(Fig 4 and Table III).
The multivariate analysis of DLQI improvement
from baseline to 6 months demonstrated that
improvement in the ustekinumab group was
significantly better than that in the other treatment
groups. Thepoint estimates for improvements inDLQIscores for ustekinumab compared with adalimumab,
etanercept, and infliximab were 1.053 (95% CI 0.430-
1.676,P= .0009), 1.061 (95%CI0.156-1.966,P= .0216),
and 1.270 (95%CI 0.075-2.465,P = .0372), respectively
(Table V). At 12 months, DLQI improvement for
ustekinumab was better compared with both
etanercept (1.917, 95% CI 0.909-2.925, P = .0002) and
adalimumab (0.743, 95% CI 0.025-1.462, P = .0427),
but was not significantly different compared with
infliximab (1.365, 95% CI 0.168 to 2.899, P = .0810)
(Table V). In addition, other factors (ie, age at
diagnosis, disease duration, ethnicity, weight, region,
and baseline PGA score, %BSA, DLQI) significantly
affected DLQI improvement (Supplemental Table IV;
available at http://www.jaad.org).DISCUSSION
Our analyses were based on data from more than
2000 patients with psoriasis who initiated a new
biologic during their participation in PSOLAR.
Effectiveness was compared between ustekinumab,
which inhibits interleukin-12/23, and 3 TNF-a
inhibitors (ie, infliximab, adalimumab, and etaner-
cept). At 6 months, 5 of the 6 comparisons for PGA
and %BSA showed significantly better effectiveness
for ustekinumab versus the TNF-a inhibitors, taking
into account several variables such as baseline
psoriasis severity and prior treatment. At 12 months,
3 of the 6 PGA and %BSA comparisons demonstrated
statistically significant better effectiveness for
ustekinumab, whereas all comparisons were
numerically better for ustekinumab. That fewer
comparisons reached statistical significance at
12 months than at 6 months may reflect that
treatment groups at 12 months were smaller (by as
much as one-third) than those at 6 months, thereby
reducing the statistical power to distinguish
significant differences.
Several factors were found to be associated with
effectiveness outcomes for biologic therapy. As
expected, patients of lower weight generally
experienced more favorable results compared with
heavier patients.27,28 More severe disease at the start
Table V. Adjusted multivariate analyses of treatment effects: analysis of covariance and least squares mean
decrease from baseline for percentage of body surface area with psoriasis and mean improvement from
baseline for Dermatology Life Quality Index scores at 6 and 12 mo
6-mo Analysis 12-mo Analysis
LSM decrease
from baseline
Point estimate*
(95% CI) P value
LSM decrease
from baseline
Point estimate*
(95% CI) P value
Mean decrease in %BSA
Infliximab 12.446% 1.807% (0.368 to 3.982) .1033 11.754% 3.945% (1.717 to 6.172) .0005
Adalimumab 12.421% 1.833% (0.670 to 2.995) .0020 14.661% 1.038% (0.06 to 2.144) .0659
Etanercept 10.835% 3.419% (1.728 to 5.110) \.0001 12.920% 2.778% (1.180 to 4.376) .0007
Ustekinumab 14.253% d d 15.699% d d
Mean improvement in DLQI
Infliximab 5.305 1.270 (0.075 to 2.465) .0372 5.563 1.365 (0.168 to 2.899) .0810
Adalimumab 5.522 1.053 (0.430 to 1.676) .0009 6.185 0.743 (0.025 to 1.462) .0427
Etanercept 5.514 1.061 (0.156 to 1.966) .0216 5.011 1.917 (0.909 to 2.925) .0002
Ustekinumab 6.575 d d 6.928 d d
%BSA, Percentage of body surface area with psoriasis; CI, confidence interval; DLQI, dermatology quality life index; LSM, least squares mean.
*Difference in LSM change from baseline compared with ustekinumab.
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but higher %BSA response. This may reflect
differences in the biology of response to therapy
for psoriasis. Small areas of moderate-to-severe
plaque can develop, even in patients who have
only minimal areas of overall involvement. The
clinical relevance of the magnitude of adjusted
differences in %BSA noted among the biologic
groups, although significant for several comparisons,
is not clear. Of note, patients with prior TNF-a
inhibitor use had worse PGA and %BSA responses
compared with bionaive patients, whereas prior
ustekinumab treatment did not have an effect on
response outcomes.
Ustekinumab showed significantly better DLQI
responses compared with each TNF-a inhibitor at
6 months, and compared with adalimumab and
etanercept at 12 months. Improvements from
baseline at both 6 and 12 months were more
apparent among patients with higher DLQI scores
($10) compared with those with lower DLQI scores
(\10) across all treatment groups. This supports the
idea that patients reporting a very large impact of
psoriasis (DLQI score$10) on daily functioning may
experience more meaningful HRQoL improvement
after appropriate treatment.
The effectiveness of biologics in PSOLAR was less
than what has been reported in randomized
controlled trials, which is consistent with other
comparative studies of psoriasis therapies.20,22,29-36
Interpretation of our results in the context of other
postapproval studies is difficult because of differ-
ences in baseline study population characteristics,
study design, adherence, and clinical end points (eg,global assessment scales) and reference treatment
groups.
Some limitations of this study design should be
considered when evaluating these results, as
PSOLAR data are derived from a day-to-day clinical
setting with wide-ranging inclusion criteria. In
particular, there may be treatment selection bias.
Consistent with this limitation, baseline demography
and disease characteristics varied among treatment
groups (eg, patients receiving infliximab had more
severe psoriasis). We attempted to adjust results for
relevant and identifiable confounding factors, but
residual confounding could exist for unmeasured
variables. Data regarding dosing adjustments were
not captured uniformly across treatment groups
thereby eliminating the possibility of stratifying
results by dose and dose interval. In addition,
relatively few patients started infliximab in
PSOLAR, thus limiting statistical power for assessing
effectiveness of infliximab in these analyses. Also
notable is the fact that more patients hadmissing data
in the smallest treatment group than in the other
groups.
Overall, effectiveness of ustekinumab was signif-
icantly better than all 3 of the TNF-a inhibitors
studied for the majority of comparisons at 6 and
12 months. Correlation with findings related to
patient-reported outcomes showed benefit with
ustekinumab treatment in nearly all comparisons at
both time points. Of note, a recent PSOLAR analysis
comparing drug survival across biologic therapies
found that ustekinumab had better drug survival
compared with all 3 TNF-a inhibitors.37 This may
reflect the findings of generally better effectiveness
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Fig 3. Psoriasis. Proportion of patients achieving clinically meaningful improvement in
Dermatology Life Quality Index (DLQI ) score ($5) by DLQI level (\10 and $10) at the time
of initiating ustekinumab, infliximab, adalimumab, or etanercept on registry: 6 (A) and 12 (B)
months.
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the current study, although several other factors may
also contribute to drug survival. In conclusion, these
analyses of PSOLAR data expand our understanding
of the comparative effectiveness of biologic agents
beyond clinical trials and help better characterize
their impact on clinical outcomes, including HRQoL,
in patients with psoriasis treated in a real-world
setting.The authors thank Cynthia Arnold, Samantha Simpson,
and ChristineWolkin (Janssen Scientific Affairs, LLC, Spring
House, PA) for their editorial assistance and writing
support of this manuscript; Kezhen L. Tang (Janssen
Research and Development, LLC, Horsham, PA) for her
statistical analysis support; and Joel Gelfand, MD, MSCE
(Hospital of the University of Pennsylvania, Philadelphia)
andmembers of the PSOLAR Scientific Advisory Committee
who provided critical review of the analytical plan for the
manuscript.
Fig 4. Psoriasis. Proportions of patients achieving Derma-
tology Life Quality Index (DLQI ) score of 0 or 1 (no impact
on health-related quality of life) at baseline and at 6 and
12 months; patients initiating ustekinumab, infliximab,
adalimumab, or etanercept on registry.
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Supplemental Table I. Most common doses and dose frequencies by treatment for patients initiating new
therapy during the registry
Ustekinumab Infliximab Adalimumab Etanercept
6 mo
No. of administrations 2012 243 1187 470
Dose 45 mg 90 mg 5 mg/kg 40 mg 50 mg
1242 (61.7) 768 (38.2) 175 (72.0) 1113 (93.8) 468 (99.6)
Dose frequency Every 12 wk Every 8 wk* Every other wk Weeklyy
996 (49.5) 603 (30.0) 97 (39.9) 969 (81.6) 241 (51.3)
12 mo
No. of administrations 1680 169 909 372
Dose 45 mg 90 mg 5 mg/kg 40 mg 50 mg
1064 (63.3) 614 (36.5) 117 (69.2) 859 (94.5) 371 (99.7)
Dose frequency Every 12 wk Every 8 wkz Every other wk Weeklyx
849 (50.5) 478 (28.5) 65 (38.5) 752 (82.7) 202 (54.3)
Data are reported as no. of doses administered (%).
*Other common dose frequencies for infliximab were other (39 [16.0%]), every 6 wk (22 [9.1%]), and every 4 wk (24 [9.9%]).
yIn addition, a large proportion (44.5%, n = 209) of etanercept doses were administered twice weekly.
zOther common dose frequencies for infliximab were other (28 [16.6%]), every 6 wk (16 [9.5%]), and every 4 wk (16 [9.5%]).
xIn addition, a large proportion (43.8%, n = 163) of etanercept doses were administered twice weekly.
J AM ACAD DERMATOL
MAY 2016
861.e1 Strober et al
Supplemental Table II. Adjusted multivariate analyses of demographic, disease, and prior treatment factors:
logistic regression for proportion of patients achieving a Physician Global Assessment score of clear (0) or
minimal (1) at 6 and 12 months
6-mo Analysis 12-mo Analysis
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age at psoriasis diagnosis/10 y 1.019 (0.943-1.101) .6282 1.055 (0.966-1.154) .2344
Duration of disease/5 y* 1.012 (0.965-1.061) .6183 1.067 (1.011-1.127) .0194
Region: European Union/Latin America vs North Americay 2.100 (1.548-2.850) \.0001 2.479 (1.726-3.561) \.0001
Non-white vs white 1.061 (0.809-1.391) .6693 1.060 (0.775-1.451) .7136
Male vs female 0.999 (0.815-1.226) .9960 0.927 (0.731-1.176) .5317
Overweight/obesity class I (25\ BMI\ 35) vs normal
(BMI\25)z
0.638 (0.487-0.837) .0012 0.607 (0.445-0.830) .0017
Obesity class II-III (BMI $35) vs normal (BMI\25)z 0.396 (0.290-0.541) \.0001 0.463 (0.323-0.664) \.0001
PsA vs no PsA 0.887 (0.721-1.091) .2565 0.859 (0.675-1.094) .2180
Smoke (current/past vs never) 0.893 (0.730-1.091) .2682 1.069 (0.848-1.347) .5730
Alcohol (current/past vs never) 1.159 (0.907-1.481) .2380 0.878 (0.665-1.160) .3602
Baseline PGA 2/3 vs 0/1x 0.439 (0.324-0.594) \.0001 0.480 (0.333-0.692) \.0001
Baseline PGA 4/5 vs 0/1x 0.397 (0.269-0.585) \.0001 0.401 (0.252-0.636) .0001
Baseline %BSA 1.003 (0.998-1.009) .2727 0.998 (0.992-1.004) .4656
DLQI $10 vs\10 0.860 (0.697-1.061) .1580 0.821 (0.642-1.048) .1138
Discontinued because of AE vs continued 0.589 (0.287-1.208) .1484 0.873 (0.386-1.974) .7440
Discontinued insurance vs continued 1.277 (0.616-2.645) .5112 1.224 (0.483-3.104) .6701
Discontinued (other reason) vs continued 1.085 (0.668-1.762) .7411 0.769 (0.439-1.345) .3565
Prior TNF-a inhibitor vs bionaive// 0.550 (0.357-0.846) .0066 0.744 (0.453-1.221) .2415
Prior ustekinumab vs bionaive 0.879 (0.508-1.518) .6431 1.433 (0.652-3.150) .3711
Prior other biologics vs bionaive 0.800 (0.597-1.073) .1365 0.891 (0.629-1.260) .5128
AE, Adverse event; BMI, body mass index; %BSA, percentage of body surface area with psoriasis; CI, confidence interval; DLQI, Dermatology
Life Quality Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; TNF, tumor necrosis factor.
*At 12 mo, patients with longer duration of psoriasis (with every 5 y of disease) were more likely to achieve PGA 0/1.
yAt 6 and 12 mo, patients living in Europe and Latin America (vs North America) were more likely to achieve PGA 0/1.
zAt 6 and 12 mo, overweight and obese patients (vs normal weight) at baseline were less likely to achieve PGA 0/1.
xAt 6 and 12 mo, patients with more severe baseline disease (PGA 2/3 and 4/5 vs 0/1) were less likely to achieve PGA 0/1.
//At 6 mo, patients with prior TNF-a inhibitor usage (vs bionaive) at baseline were less likely to achieve PGA 0/1.
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Supplemental Table III. Adjusted multivariate analyses of demographic, disease, and prior treatment factors:
analysis of covariance for decrease from baseline in percentage of body surface area with psoriasis at 6 and
12 months
6-mo Analysis 12-mo Analysis
Point estimate (95% CI) P value Point estimate (95% CI) P value
Age at psoriasis diagnosis/10 y 0.129 (0.262 to 0.520) .5172 0.098 (0.265 to 0.460) .5973
Duration of disease/5 y 0.008 (0.235 to 0.251) .9490 0.002 (0.227 to 0.223) .9876
Region: European Union/Latin
America vs North America
0.790 (2.271 to 0.690) .2952 0.944 (2.313 to 0.426) .1768
Non-white vs white* 1.760 (0.352 to 3.167) .0143 1.160 (0.163 to 2.483) .0856
Male vs female 0.441 (0.594 to 1.476) .4034 0.103 (0.873 to 1.078) .8367
Overweight/obesity class I
(25\ BMI\ 35) vs normal (BMI\25)
0.963 (0.378 to 2.305) .1592 0.663 (0.567 to 1.892) .2907
Obesity class II-III (BMI $35)
vs normal (BMI\25)y
3.343 (1.778 to 4.908) \.0001 2.518 (1.053 to 3.982) .0008
PsA vs no PsA 0.541 (0.527 to 1.609) .3205 0.125 (1.133 to 0.883) .8074
Smoke (current/past vs never) 0.537 (1.555 to 0.481) .3010 0.420 (1.371 to 0.531) .3865
Alcohol (current/past vs never)z 1.590 (2.820 to 0.360) .0113 0.862 (1.991 to 0.268) .1348
Baseline PGA 2/3 vs 0/1 0.968 (0.639 to 2.574) .2376 0.030 (1.556 to 1.497) .9697
Baseline PGA 4/5 vs 0/1 0.875 (1.118 to 2.867) .3894 0.320 (2.218 to 1.578) .7406
Baseline %BSAx 0.792 (0.819 to 0.765) \.0001 0.812 (0.838 to 0.787) \.0001
DLQI $10 vs DLQI\10 0.710 (1.766 to 0.346) .1874 0.946 (1.944 to 0.052) .0632
Discontinued because of AE vs continued 2.718 (6.365 to 0.930) .1441 1.549 (4.948 to 1.849) .3713
Discontinued insurance vs continued// 3.212 (6.948 to 0.524) .0919 4.231 (8.070 to 0.392) .0308
Discontinued (other reason) vs continued 0.663 (3.177 to 1.851) .6051 1.636 (4.026 to 0.755) .1797
Prior TNF-a inhibitor vs bionaive{ 2.954 (0.699 to 5.210) .0103 3.506 (1.363 to 5.650) .0014
Prior ustekinumab vs bionaive 0.208 (2.608 to 3.023) .8850 0.917 (4.165 to 2.331) .5796
Prior other biologics vs bionaive 0.797 (0.711 to 2.305) .3000 1.279 (0.183 to 2.742) .0864
AE, Adverse event; BMI, body mass index; %BSA, percentage of body surface area with psoriasis; CI, confidence interval; DLQI, Dermatology
Life Quality Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; TNF, tumor necrosis factor.
*At 6 mo, non-white ethnicity (vs white) was significantly associated with worse %BSA response.
yAt 6 and 12 mo, heavier weight (obesity class II/III vs normal weight) was significantly associated with worse %BSA response.
zAt 6 mo, current/past alcohol use (vs never used) was associated with better %BSA response.
xAt 6 and 12 mo, higher (worse) baseline %BSA at baseline was associated with better %BSA response.
//At 12 mo, discontinuation from the registry because of insurance (vs continuing) was associated with better %BSA response.
{At 6 and 12 mo, previous treatment with TNF-a inhibitors (vs bionaive) was significantly associated with worse %BSA response.
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Supplemental Table IV. Adjusted multivariate analyses of demographic, disease, and prior treatment factors:
analysis of covariance for improvement from baseline in Dermatology Life Quality Index at 6 and 12 months
6-mo Analysis 12-mo analysis
Point estimate (95% CI) P value Point estimate (95% CI) P value
Age at psoriasis diagnosis/10 y* 0.391 (0.181 to 0.602) .0003 0.255 (0.024 to 0.486) .0302
Duration of disease/5 yy 0.131 (0.000 to 0.262) .0496 0.086 (0.060 to 0.232) .2482
Region: European Union/Latin
America vs North Americaz
1.064 (1.856 to 0.272) .0085 0.885 (1.780 to 0.009) .0524
Non-white vs white* 0.785 (0.027 to 1.542) .0423 0.819 (0.024 to 1.662) .0567
Male vs female 0.383 (0.174 to 0.941) .1777 0.364 (0.265 to 0.993) .2563
Overweight/obesity class I
(25\ BMI\ 35) vs normal (BMI\25)
0.613 (0.105 to 1.331) .0942 0.695 (0.103 to 1.492) .0878
Obesity class II-III (BMI $35)
vs normal (BMI\25)x
0.568 (0.269 to 1.405) .1830 1.004 (0.065 to 1.943) .0361
PsA vs no PsA 0.297 (0.869 to 0.275) .3084 0.228 (0.415 to 0.872) .4860
Smoke (current/past vs never) 0.475 (1.024 to 0.074) .0900 0.272 (0.884 to 0.340) .3838
Alcohol (current/past vs never) 0.535 (1.202 to 0.131) .1155 0.467 (1.188 to 0.254) .2043
Baseline PGA 2/3 vs 0/1// 1.278 (2.163 to 0.394) .0047 0.965 (1.937 to 0.007) .0518
Baseline PGA 4/5 vs 0/1// 2.021 (3.108 to 0.935) .0003 2.701 (3.911 to 1.491) \.0001
Baseline %BSA// 0.041 (0.056 to 0.027) \.0001 0.048 (0.064 to 0.032) \.0001
DLQI $10 vs DLQI\10// 8.049 (8.613 to 7.486) \.0001 8.493 (9.132 to 7.853) \.0001
Discontinued because of AE vs continued 0.410 (1.546 to 2.365) .6812 0.137 (2.142 to 2.416) .9061
Discontinued insurance vs continued 0.140 (1.831 to 2.111) .8890 0.197 (2.708 to 2.314) .8778
Discontinued (other reason) vs continued 0.820 (0.535 to 2.175) .2356 1.201 (0.338 to 2.741) .1260
Prior TNF-a inhibitor vs bionaive 0.842 (0.374 to 2.058) .1746 0.146 (1.231 to 1.522) .8357
Prior ustekinumab vs bionaive 0.163 (1.752 to 1.427) .8411 0.104 (2.069 to 2.277) .9251
Prior other biologics vs bionaive 0.284 (0.535 to 1.102) .4966 0.029 (0.930 to 0.988) .9530
AE, Adverse event; BMI, body mass index; %BSA, percentage of body surface area with psoriasis; CI, confidence interval; DLQI, Dermatology
Life Quality Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; TNF, tumor necrosis factor.
*At 6 and 12 mo, older age at psoriasis diagnosis (by every 10 y) and non-white ethnicity (vs white) were significantly associated with a
worsened DLQI response.
yAt 6 mo, longer duration of disease (by every 5 y) was associated with a worsened DLQI response.
zAt 6 mo, European and Latin American location (vs North America) was significantly associated with a better DLQI response.
xAt 12 mo, obesity class II-III (vs normal weight) was associated with a worsened DLQI response.
//At 6 and 12 mo, more severe disease at baseline (as indicated by PGA 4/5 and 2/3 vs 0/1; larger [worse] %BSA; and larger [worse] DLQI score
[$10 vs\10]) were significantly associated with a better DLQI response.
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